- Home
- FLYE vs APLM Comparison
FLYE vs APLM Comparison
Compare FLYE & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- APLM
- Stock Information
- Founded
- FLYE 2018
- APLM 2016
- Country
- FLYE United States
- APLM United States
- Employees
- FLYE N/A
- APLM N/A
- Industry
- FLYE Aerospace
- APLM Blank Checks
- Sector
- FLYE Industrials
- APLM Finance
- Exchange
- FLYE Nasdaq
- APLM Nasdaq
- Market Cap
- FLYE 91.6M
- APLM 6.1M
- IPO Year
- FLYE 2024
- APLM N/A
- Fundamental
- Price
- FLYE $0.80
- APLM $8.56
- Analyst Decision
- FLYE
- APLM
- Analyst Count
- FLYE 0
- APLM 0
- Target Price
- FLYE N/A
- APLM N/A
- AVG Volume (30 Days)
- FLYE 4.1M
- APLM 37.1K
- Earning Date
- FLYE 08-19-2025
- APLM 09-26-2025
- Dividend Yield
- FLYE N/A
- APLM N/A
- EPS Growth
- FLYE N/A
- APLM N/A
- EPS
- FLYE N/A
- APLM N/A
- Revenue
- FLYE $22,881,935.00
- APLM $198,000.00
- Revenue This Year
- FLYE N/A
- APLM $415.15
- Revenue Next Year
- FLYE N/A
- APLM N/A
- P/E Ratio
- FLYE N/A
- APLM N/A
- Revenue Growth
- FLYE N/A
- APLM N/A
- 52 Week Low
- FLYE $0.51
- APLM $3.66
- 52 Week High
- FLYE $8.30
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- FLYE 28.69
- APLM 72.67
- Support Level
- FLYE $0.72
- APLM $3.66
- Resistance Level
- FLYE $0.86
- APLM $6.37
- Average True Range (ATR)
- FLYE 0.08
- APLM 0.80
- MACD
- FLYE 0.15
- APLM 0.33
- Stochastic Oscillator
- FLYE 65.19
- APLM 76.39
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.